These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36761724)

  • 41. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
    Amedei A; Niccolai E; Prisco D
    Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
    Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
    Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.
    Panni UY; Chen MY; Zhang F; Cullinan DR; Li L; James CA; Zhang X; Rogers S; Alarcon A; Baer JM; Zhang D; Gao F; Miller CA; Gong Q; Lim KH; DeNardo DG; Goedegebuure SP; Gillanders WE; Hawkins WG
    Cancer Immunol Immunother; 2023 Aug; 72(8):2813-2827. PubMed ID: 37179276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8
    Duperret EK; Perales-Puchalt A; Stoltz R; G H H; Mandloi N; Barlow J; Chaudhuri A; Sardesai NY; Weiner DB
    Cancer Immunol Res; 2019 Feb; 7(2):174-182. PubMed ID: 30679156
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A liposomal RNA vaccine inducing neoantigen-specific CD4
    Salomon N; Vascotto F; Selmi A; Vormehr M; Quinkhardt J; Bukur T; Schrörs B; Löewer M; Diken M; Türeci Ö; Sahin U; Kreiter S
    Oncoimmunology; 2020 Jun; 9(1):1771925. PubMed ID: 32923128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.
    Dobrovolskienė N; Pašukonienė V; Darinskas A; Kraśko JA; Žilionytė K; Mlynska A; Gudlevičienė Ž; Mišeikytė-Kaubrienė E; Schijns V; Lubitz W; Kudela P; Strioga M
    Vaccine; 2018 Jul; 36(29):4171-4180. PubMed ID: 29895501
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
    Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
    J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.
    Chen J; Guo XZ; Li HY; Wang D; Shao XD
    Exp Biol Med (Maywood); 2015 Oct; 240(10):1310-8. PubMed ID: 25736302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.
    Ding Z; Li Q; Zhang R; Xie L; Shu Y; Gao S; Wang P; Su X; Qin Y; Wang Y; Fang J; Zhu Z; Xia X; Wei G; Wang H; Qian H; Guo X; Gao Z; Wang Y; Wei Y; Xu Q; Xu H; Yang L
    Signal Transduct Target Ther; 2021 Jan; 6(1):26. PubMed ID: 33473101
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.
    Collignon A; Perles-Barbacaru AT; Robert S; Silvy F; Martinez E; Crenon I; Germain S; Garcia S; Viola A; Lombardo D; Mas E; Béraud E
    Oncotarget; 2015 Sep; 6(27):23462-79. PubMed ID: 26405163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4.
    Kang TH; Kim YS; Kim S; Yang B; Lee JJ; Lee HJ; Lee J; Jung ID; Han HD; Lee SH; Koh SS; Wu TC; Park YM
    Oncotarget; 2015 Sep; 6(29):27751-62. PubMed ID: 26336989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers.
    Zheng C; Fass JN; Shih YP; Gunderson AJ; Sanjuan Silva N; Huang H; Bernard BM; Rajamanickam V; Slagel J; Bifulco CB; Piening B; Newell PHA; Hansen PD; Tran E
    Cancer Cell; 2022 Apr; 40(4):410-423.e7. PubMed ID: 35413272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient.
    Gao S; Wang J; Zhu Z; Fang J; Zhao Y; Liu Z; Qin H; Wei Y; Xu H; Dan X; Yang L; Xu Q
    Immunotherapy; 2023 Feb; 15(2):57-69. PubMed ID: 36651232
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
    Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
    Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
    Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
    Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
    Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
    J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.